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While offering many practical advantages for cell-based 
screening, cells grown on tissue culture plastic lack normal 
cell-cell and cell-matrix interactions, resulting in deregulated 
growth, dedifferentiation, disruption of other processes, and a 
poor simulation of the in vivo (patho)physiology.1 3D cell cul-
ture methods have been developed that enable a more in vivo 
like tissue architecture and are therefore expected to represent 
a more physiologically relevant context for the evaluation of 
bioactive molecules.2–4 Although gaining in popularity for 
small-scale analyses, 3D cultures have yet to be widely adopted 
for screening. A number of factors account for this, although 
high-throughput 3D imaging and the analysis of large and 
complex image data sets can represent the most significant 
barrier to the implementation of high-content 3D culture-based 
screening.5 As a result, where 3D assays are used for screening, 
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Abstract
3D tissue cultures provide a more physiologically relevant context for the screening of compounds, compared with 2D cell 
cultures. Cells cultured in 3D hydrogels also show complex phenotypes, increasing the scope for phenotypic profiling. Here 
we describe a high-content screening platform that uses invasive human prostate cancer cells cultured in 3D in standard 
384-well assay plates to study the activity of potential therapeutic small molecules and antibody biologics. Image analysis 
tools were developed to process 3D image data to measure over 800 phenotypic parameters. Multiparametric analysis 
was used to evaluate the effect of compounds on tissue morphology. We applied this screening platform to measure the 
activity and selectivity of inhibitors of the c-Met and epidermal growth factor (EGF) receptor (EGFR) tyrosine kinases in 
3D cultured prostate carcinoma cells. c-Met and EGFR activity was quantified based on the phenotypic profiles induced by 
their respective ligands, hepatocyte growth factor and EGF. The screening method was applied to a novel collection of 80 
putative inhibitors of c-Met and EGFR. Compounds were identified that induced phenotypic profiles indicative of selective 
inhibition of c-Met, EGFR, or bispecific inhibition of both targets. In conclusion, we describe a fully scalable high-content 
screening platform that uses phenotypic profiling to discriminate selective and nonselective (off-target) inhibitors in a 
physiologically relevant 3D cell culture setting.
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the most common end-point measurements tend to be bio-
chemical determinations of cell viability, with the loss of 
potentially valuable phenotypic information.
Cells cultured in extracellular matrix (ECM)–containing 
hydrogels can generate complex multicellular tissues, sup-
porting a higher level of tissue organization, such as forma-
tion of ductal structures by epithelial cells and complex 
networks of invasive tumor cells.6–10 These features may be 
relevant to the pathology of the disease being studied and 
offer a context for screening for therapeutic molecules. 
Complex phenotypes can also be exploited for compound 
profiling, allowing compounds that affect different targets 
and therefore induce different phenotypes to be discrimi-
nated, potentially providing additional information on the 
biological effects of compounds that cannot be obtained 
from single end-point measurements.
In many cultured cells, activation of receptor tyrosine 
kinases results in increased proliferation and motility.11 Cell 
motility has previously been used as a readout for high-
throughput small-molecule and small interfering RNA 
(siRNA) screens for inhibitors of c-Met signaling.12–14 In 
3D culture, activation of c-Met can result in invasion of 
tumor cells into the surrounding microenvironment,15 a pro-
cess that closely resembles the in vivo pathophysiology. 
Similarly, activation of the epidermal growth factor (EGF) 
receptor is known to induce epithelial- to mesenchymal 
transition (EMT) and invasion in various cancer types.16,17 
As expected, selective inhibition of the receptor tyrosine 
kinases inhibits the ligand-induced effects. However, com-
pounds that inhibit multiple targets or are toxic may also 
inhibit ligand-induced effects. Here, we describe a 384-well 
screening assay that uses automated high-content analysis 
and profiling of 3D cultures of invasive prostate cancer 
tumor cells to identify selective inhibitors of the c-Met and 
EGF receptor (EGFR) tyrosine kinases.
Materials and Methods
Cell Lines
The human prostate adenocarcinoma cell line PC-3 was cul-
tured in Dulbecco’s modified Eagle’s medium (DMEM)–F12 
(Ham’s) growth medium (Gibco Fisher Scientific, Landsmeer, 
Netherlands), supplemented with 10% fetal bovine serum 
(FBS) (Gibco Fisher Scientific), 1 mM sodium pyruvate 
(Gibco Fisher Scientific), 1.5 g/L NaHCO3 (Merck, Schiphol-
Rijk, Netherlands), 0.1 mM nonessential amino acids (Gibco 
Fisher Scientific), and 50 µg/mL gentamycin (Sigma Aldrich, 
Zwijndrecht, Netherlands). PC-3 cells were grown in 175-cm2 
tissue culture flasks (Corning, Amsterdam, Netherlands) in 
culture medium as described above. Before reaching maximal 
density, cells were washed with 1× phosphate-buffered saline 
(PBS) (Sigma Aldrich) and trypsinized with 1× Trypsin (Gibco 
Fisher Scientific). Subsequently, medium was added and cells 
were pelleted by centrifugation and resuspended in FBS with 
10% DMSO (Biosolve B.V., Valkenswaard, Netherlands) and 
stored in aliquots at −150 °C.
3D Invasion Assay
PC-3 cells were cultured in 384-well plates (Greiner Bio-One 
B.V., Alphen aan den Rijn, Netherlands) in 60% v/v growth 
factor–reduced Matrigel (>9 mg/mL) (Corning), which sup-
ported spheroid formation of the highly transformed PC-3 cells 
and invasion upon addition of motogenic cytokines. To gener-
ate gels, thawed cells were mixed with culture medium and 
growth factor–reduced Matrigel. Then, 14.5 µL of cell-gel mix 
was added to each well of a 384-well plate using a CyBi Selma 
96/60 robotic liquid handler (Analytik Jena AG, Jena, 
Germany), at a final cell density of 2000 cells per well. After 
polymerization at 37 °C for 30 min, DMEM-F12 (Ham’s) 
growth medium containing growth factors (hepatocyte growth 
factor [HGF] or EGF) and compounds were added to the gel. 
The plate(s) were subsequently covered with a gas-permeable 
adhesive membrane (Thermo Scientific, Zwijndrecht, 
Netherlands). Compound exposures were performed for 96 h, 
after which gels were fixed with 3% formaldehyde (Sigma 
Aldrich), permeabilized with 0.2% Triton-X100 (Sigma 
Aldrich), and stained with 0.25 µM rhodamine-phalloidin 
(Sigma Aldrich) and 0.1% Hoechst 33258 (Sigma Aldrich) in 
PBS at 4 °C for 16 h. After staining, plates were washed in 
PBS and covered with a Greiner SilverSeal (Greiner Bio-One 
B.V., Alphen aan den Rijn, Netherlands).
Compounds
Anti c-Met and nontargeting control Fab antibodies were gen-
erously provided by Merus Biopharmaceuticals B.V. (Utrecht, 
Netherlands). c-Met inhibitor ArQ-197 (Tivantinib) was syn-
thesized by Janssen Pharmaceutica NV (Beerse, Belgium), fol-
lowing the synthesis method published from ArQule, and 
subsequently sent to the authors as a gift from Souichi Ogata 
(Janssen Oncology R&D). Results were confirmed using a 
second source of ArQ-197 (SelleckChem/Bio-Connect B.V. 
Huissen, Huissen, Netherlands). EGFR inhibitor AG1478 was 
obtained from Santa Cruz (SC-200613; Bio-Connect B.V. 
Huissen). PHA-665752 was a gift from Pfizer, Inc. (La Jolla, 
CA, USA). A collection of 80 compounds selected to inhibit 
both EGFR and/or c-Met was generated by Vichem Chemie 
(Budapest, Hungary) (Suppl. Table S1).
Imaging
A BD Pathway 855 automated inverted fluorescence micro-
scope (BD Biosciences, Breda, Netherlands) was used for 
automated imaging of 384-well plates (wide-field epifluo-
rescence). This microscope was used to image both Hoechst 
33258 and rhodamine-phalloidin staining, using a 4× 
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Olympus objective, at focal planes spaced at intervals of 50 
µm throughout the gel using Attovision software (BD 
Biosciences, Breda, Netherlands) accompanying the micro-
scope. The gel was imaged through its entire depth (z-axis), 
requiring 25 images per well. Each image captured approxi-
mately 75% of the area of the well.
Data Analysis
Ominer image analysis software (OcellO, Leiden, Netherlands) 
and KNIME (https://www.knime.org) were used to extract in-
focus information from the Z-stacks generated by the BD 
Pathway 855 (BD Biosciences) for both Hoechst 33258 
(nuclei) and rhodamine-phalloidin (F-actin) using maximum-
intensity projections.18 For image processing, a monochrome 
mask was created for both channels to define the regions of 
interest (ROIs). The in-focus images were used to quantify 
staining intensities and a set of Hu moments and Gabor 
wavelet-based features describing image intensity and texture. 
The Hoechst 33258–derived monochrome mask was used to 
determine number and area of nuclei and tumoroids. In addi-
tion, a detailed set of parameters was calculated to describe the 
shape of the rhodamine-phalloidin (F-actin) stained objects.18 
First, for principal components analysis, data were Z score nor-
malized to the negative control treatment median to account 
for plate-to-plate differences. The features derived from the 
image analysis and quantification steps were ranked based on 
their ability to distinguish positive and negative controls (Z′), 
and the features that showed greatest separation between con-
trol groups were retained (Z′ > –1.0). The median of treatment 
quadruplicates was used for a principal component analysis 
(PCA) that combined correlated features into (uncorrelated) 
principal components. This model was applied to all wells and 
summarized ~95% of all variation into principal components. 
The distance between treatment and control groups was quan-
tified as a Z score in principal component 0 (PC0), which 
retained 60% of the variation of the data set. 2D density esti-
mations and linear discriminant analysis (LDA) were per-
formed using the MASS package (http://www.stats.ox.ac.uk/
pub/MASS4/)19 for R-Studio 0.99.878 (https://www.rstudio.
com/products/rstudio2/) with R 3.2.3 (https://www.r-project.
org/). PCA was calculated in KNIME, and principal compo-
nent plots were generated using ggplot2 (http://ggplot2.org/)20 
with the scatterplot3D package for R-Studio 0.99878 (https://
cran.r-project.org/web/packages/scatterplot3d/index.html).21 
Other charts were generated using GraphPad Prism 6 software 
(GraphPad Software, La Jolla, CA). Results are displayed as 
mean ± standard deviation unless otherwise stated.
Western Blot Detection of Receptor Activation
Phosphorylation status of c-Met and EGFR in response to 20 
ng/mL HGF or 20 ng/mL EGF was evaluated by Western blot. 
Briefly, 105 PC-3 cells were grown per well in 12-well plates. 
After 24 h, growth medium was replaced with starvation 
medium (without serum and antibiotics) containing test com-
pounds. After 24 h of compound exposure, growth factors (20 
ng/mL HGF/EGF) were added for 10 min. Protein was isolated 
using RIPA lysis buffer (1% w/w deoxycholate, 50 mM Tris 
[pH 7.5], 0.15 M NaCl, 0.1% sodium dodecyl sulfate [SDS], 
1% NP-40, 2 mM EDTA, 1% protease inhibitor cocktail 
[Sigma Aldrich]) and quantified using the standard bicincho-
ninic acid (BCA) method according to the manufacturer’s 
instructions (Thermo Scientific). Western blot analysis was 
performed according to a standard protocol using phospho-c-
Met (Tyr1234/1235) antibody (3077P; Cell Signaling) 
diluted 1:1000 in 5% BSA in TBS-T or phospho-EGFR 
(Tyr1173) (4407; Cell Signaling Technology B.V., Leiden, 
Netherlands) 1:1000 in 5% BSA in Tris-Buffered Saline 
with 0.05% Tween-20 (TBS-T). Phospho-c-Met and phos-
pho-EGFR antibodies were detected using horseradish per-
oxidase (HRP)–conjugated anti–rabbit IgG secondary 
antibody (111-035-003; JacksonImmunoResearch, Suffolk, 
UK) and ECL Plus reagent (RPN2132; GE Healthcare Life 
Sciences, Eindhoven, Netherlands). Detection of antibody was 
performed using a LAS4000 scanner (GE Healthcare Life 
Sciences). Tubulin loading control was detected using an anti-
Tubulin antibody (T-9026; Sigma-Aldrich) diluted 1:1000 in 
5% BSA in TBS-T and an anti-mouse Alexa 647–linked IgG 
(115-605-006; JacksonImmunoResearch). The Alexa 647 sig-
nal was detected directly using the LAS4000.
In Vitro Kinase Activity Measurement
EGFR enzyme activity was assayed in 384 microtiter plates 
(Corning 3676) at three compound concentrations, in a total 
volume of 10 µL by the Transcreener ADP2 FP method 
(BellBrook Labs, Madison, WI). Assay buffer contained 20 
mM HEPES (pH 7.5), 1 mM dithiothreitol (DTT), 10 mM 
MgCl2, 2 mM MnCl2, and 0.01% v/v NP40. The final EGFR 
concentration was 7 nM. Poly Glu-Tyr (4:1)/poly Glu-Tyr 
(4:1) was used as substrate at a final concentration of 0.01 
mg/mL. The final adenosine triphosphate (ATP) concentra-
tion was at 7.52 µM. The enzyme reaction was incubated 
for 60 min and stopped by addition of 10 µL adenosine 
diphosphate (ADP) detection mixture (1×). Measurements 
were performed on a Tecan (Männedorf, Switzerland). 
Infinite M1000Pro reader. c-Met enzyme activity was 
assayed in 384 microtiter plates (Corning 3676) at three 
compound concentrations, in a total volume of 10 µL by the 
Transcreener ADP2 FP method (BellBrook Labs). Assay 
buffer contained 20 mM HEPES (pH 7.5), 1 mM DTT, 3 
mM MgCl2, 3 mM MnCl2, and 0.01% v/v Tween-20. The 
final c-Met concentration was 8 nM. Poly Ala-Glu-Lys-Tyr 
(6:2:5:1) was used as substrate at a final concentration of 
0.25 mg/mL. The final ATP concentration was at 9.6 µM. 
The enzyme reaction was incubated for 60 min and stopped 
by addition of 10 µL ADP detection mixture (1×). 
Measurements were performed using a Tecan Infinite 
M1000Pro reader.
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Results
Quantification of Complex Phenotypic Changes 
of Prostate Cancer Cells Cultured in 3D in 384-
Well Microplates
We developed a 3D cell culture screening method for tumor 
cell invasion driven by c-Met and EGFR. PC-3 cells were cul-
tured in ECM protein-rich hydrogels in 384-well plates in the 
presence or absence of c-Met/EGFR agonists and antagonists. 
After fixation and staining with rhodamine-phalloidin to reveal 
the structure of prostate cancer tumoroids and Hoechst 33258 
to label nuclei, gels were imaged in two fluorescence channels 
using a BD Pathway 855 (BD Biosciences), collecting paired 
stacks of xy images throughout the z-plane for each well. 
In-focus information from each image was extracted and a 
single xy image projection was generated (Suppl. Fig. S1).
In the absence of added c-Met or EGFR agonists, PC-3 
cells developed into spheroids over a period of 4 days (Fig. 
1A, upper panel). Treatment with the c-Met ligand (HGF) or 
the EGFR ligand (EGF) induced a highly invasive phenotype 
(Fig. 1A, middle and lower panels). To quantify these pheno-
typic changes in detail, Ominer and KNIME software were 
used to identify and quantify different morphological features 
from the 2D projections of the cytoskeleton and nuclei-derived 
image stacks. To do this, a collection of different image analy-
sis algorithms was applied to derive measurements of the 
shape and fluorescence intensity of individual tumoroids, 
wavelets, and Hu and Zernike moments as previously 
described.22 Supervised PCA was used to reduce measure-
ments from approximately 800 phenotypic parameters to prin-
cipal components (PCs). EGF-treated and untreated PC-3 cells 
were used to train a profile to represent active and inactive 
EGFR inhibitors, respectively, which was subsequently scaled 
to percent stimulation. Similarly, a separate supervised analy-
sis was performed that was trained with HGF-treated and 
untreated cells to separate phenotypes representing active 
c-Met from unstimulated control phenotypes. The primary 
principal component (PC0) was plotted for both EGF- and 
HGF-induced phenotypic changes to visualize the responses 
(Fig. 1B). Both HGF- and EGF-induced phenotypes of PC-3–
derived tumoroids could be clearly discriminated from 
untreated tissues. Many of the phenotypic features separating 
HGF- and EGF- induced changes in phenotype from unstimu-
lated controls describe shape, circularity, and intensity. The 
distance in phenotypic space along PC0 to the unstimulated 
controls was presented graphically as a function of EGF or 
HGF concentration (Fig. 1C).
Phenotypic Profiling Can Be Used to Quantify 
c-Met Activation and Inactivation
To test whether HGF-induced phenotypes could report c-Met 
activation, HGF was added in the presence of the c-Met 
function blocking Fab antibody, Genentech 5D5 Fab 
(Genentech, South San Francisco, CA). 5D5 antibody effec-
tively inhibited the HGF-induced response (PC0, Fig. 2A), 
resulting in phenotypes that projected in a similar location to 
unstimulated controls in phenotypic space (represented by 
three principal components), with an inhibition that was dose 
dependent (Fig. 2A,B). The c-Met inhibitory antibody had no 
quantifiable effect on the PC-3 phenotype in the absence of 
HGF (Fig. 2A). In contrast, treatment of PC-3 cells with a 
c-Met activating antibody, the bivalent IgG form of 5D5, 
which crosslinks c-Met, induced a phenotype that was indistin-
guishable from that induced by HGF. Together these results 
confirm the c-Met dependency of the HGF-induced phenotype 
and demonstrate that principal components can be used to 
quantify HGF-induced phenotypic changes correlating with 
c-Met activation and inhibition.
Using Phenotype to Discriminate Compounds 
Based on Target Selectivity
To determine whether the phenotypic assay can discrimi-
nate between selective c-Met and EGF inhibitors, PC-3 
cells were cultured in the presence of either HGF or EGF, 
together with established small-molecule and antibody 
inhibitors of their cognate receptors. As expected, the small-
molecule c-Met inhibitor PHA-66575223,24 selectively 
inhibited the phenotype induced by HGF. In contrast, the 
EGFR inhibitor AG147825 had no significant effect on the 
HGF-induced phenotype up to a concentration of 1 µM 
(Fig. 3A,C, right panel). Conversely, AG1478 but not PHA-
665752 inhibited the EGF-induced phenotype (Fig. 3A,C, 
left panel). These findings suggest that residual c-Met and 
EGFR activity does not contribute to the 3D phenotype 
under the conditions used and that c-Met does not require 
EGFR for the ligand-induced response and vice versa. 
Interestingly, ArQ-197, which is reported to be a selective 
inhibitor of c-Met,22,26 inhibited both the HGF- and EGF-
induced responses with a similar IC50, suggesting a more 
complex mechanism of action. At higher concentrations (>1 
µΜ), this compound introduced a novel phenotype, shown 
by a shift away from the controls in a representation of phe-
notypic space (Fig. 3B).
To confirm that the interpretations based on phenotypic 
changes correlated with inhibition of receptor kinase activ-
ity, we performed Western blot analysis for phosphorylated 
c-Met (Y1234/-5) and phosphorylated EGFR (Y1173) (Fig. 
3D). Results showed that PHA-665752 and the Genentech 
5D5 Fab potently inhibited phosphorylation of c-Met but 
not EGFR phosphorylation. Conversely, AG1478 and 
cetuximab treatment inhibited phosphorylation of EGFR 
but not of c-Met. ArQ-197 did not show detectable inhibi-
tion of EGFR (Y1173) or c-Met (Y1234/-5) phosphoryla-
tion under these conditions (Fig. 3D). Therefore, inhibition 
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of phenotypes in 3D culture by c-Met and EGFR inhibitors 
correlates with inhibition of the respective kinases.
Taken together, these results show that measurement of 
ligand-induced phenotypic changes can be used to discrimi-
nate and measure inhibition of c-Met and EGFR.
Using Phenotypic Profiles to Identify Novel 
Selective c-Met and EGFR Inhibitors
Using data obtained from c-Met and EGFR in vitro kinase 
assays, a collection of 80 putative single- and dual-specific-
ity EGFR and c-Met inhibitors was compiled (Suppl. Table 
S1), which included several well-characterized reference 
compounds. These were screened in 3D-cultured PC-3 cells 
together with several published reference inhibitors of 
c-Met and EGFR. All compounds were screened in 384-
well plates at three concentrations (10 µM, 3.16 µM, and 1 
µM) in triplicate plates in both EGF- and HGF-stimulated 
conditions. Multiparametric analysis was performed as 
before, followed by Z score normalization of each parame-
ter to the plate median. Supervised PCA was used to con-
dense phenotypic measurements to one phenotypic 
descriptor (PC0), which was scaled to percent inhibition. 
PCA was found to perform superior to individual features in 
separating out stimulated and unstimulated controls (Suppl. 
Fig. S2).
Figure 4A depicts the screening results combining the 
first principal component, PC0, for both EGF- and HGF-
induced phenotypic changes in a single plot. Inhibition of 
c-Met is therefore represented by a decrease in the c-Met 
Figure 1. Receptor activation induces a quantifiable change in phenotype. (A) Typical images of unstimulated, hepatocyte 
growth factor (HGF)–stimulated, and epidermal growth factor (EGF)–stimulated PC-3 cells taken using a Nikon TI Eclipse 
confocal microscope (Nikon, Tokyo, Japan). Receptor activation induced a change in phenotype characterized by invasion into the 
surrounding matrix. F-actin stained red; nuclei stained blue. (B) Phenotypic shift induced by HGF and EGF visualized using supervised 
(unstimulated-stimulated) principal components analysis (PCA). PC0 was scaled between 0% (unstimulated) and 100% (stimulated). 
Individual data points shown, as well as mean and standard deviations. (C) EGF and HGF cause a dose-dependent change in 
phenotype. Phenotypic change is derived from PC0 and scaled to percent response, as shown in B. Results are shown as means with 
standard deviation.
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PC0 value, from the growth factor–treated to growth factor–
untreated controls. Compounds that induced such a shift in 
the c-Met PC0 included various established c-Met reference 
inhibitors that were included in the screen, including the 
Genentech 5D5 Fab antibody, foretinib, and lower doses of 
PHA-665752. This confirmed that the phenotypic training 
using HGF-treated and untreated samples discriminated 
c-Met active and inactive conditions and was able to select 
compounds that induced a c-Met inhibitory phenotypic pro-
file. Selective inhibition of the EGFR could be character-
ized by a horizontal shift to the left, from a profile associated 
with an EGF-stimulated phenotype to one associated with 
an unstimulated phenotype. This region contained several 
EGFR reference inhibitors, including erlotinib, gefitinib, 
and AG1478 (at 1 and 3.16 µM), which were included in the 
screen alongside test compounds. Compounds that clus-
tered together with the unstimulated controls (Fig. 4A, bot-
tom left quadrant) were predicted to have a dual-inhibitory 
activity for both c-Met and EGFR. The compounds cluster-
ing in this area included afatinib and also a number of previ-
ously untested compounds of the Vichem library. The class 
to which each compound was attributed using this approach 
is shown in Table 1 and Supplemental Table S2. By using 
another form of supervised clustering, linear discriminant 
analysis (LDA), we could separate the highly similar EGF- 
and HGF-induced phenotypes into a multidimensional plot 
(Suppl. Fig. S3). However, this approach did not improve 
classification of reference c-Met and EGFR inhibitor 
compounds.
Representative images of 3D-cultured PC-3 cells treated 
with EGFR and c-Met inhibitors are presented in Figure 4B 
and show a consistency between the automated classifica-
tion of compounds to a specific inhibitory class and the 
phenotype that is induced in the presence of a specific 
growth factor. We compared the phenotypic classification 
of compounds with measurements of EGFR or c-Met 
enzyme inhibitory activity (Table 2 and Suppl. Table S3). 
Phenotypic classification was found to frequently overlap 
with biochemical measurements. Inhibition of c-Met activ-
ity in enzymatic and phenotypic assays was closely corre-
lated, with all compounds showing greater than 40% 
inhibition in an enzymatic assay being inhibitory in the phe-
notypic assay at the equivalent concentration. However, 
approximately half of the compounds that were active in 
EGFR enzymatic assays were inactive in the cell-based 
phenotypic assays. Furthermore, several of the compounds 
that were inhibitory at the lowest doses in the EGFR enzy-
matic assay only showed activity in the corresponding phe-
notypic assay at higher concentrations (e.g., VCC833029:24, 
VCC740005:11, and VCC407451:10), indicating lower 
sensitivity of the phenotypic assay compared to the enzy-
matic assay. Not all compounds that induced enzymatic 
inhibition of EGFR and/or c-Met could be identified as 
inhibitors from our screening results, suggesting that enzy-
matic inhibition does not directly translate to a phenotypic 
change under all conditions.
We then compared ranking of compounds based on phe-
notypic profiling with ranking based on cell count. Cell 
count was determined by the number of nuclei counted per 
well (one of the many features scored by the multiparamet-
ric analysis) and is a feature that correlates closely with bio-
chemical measurements of cell proliferation (not shown). 
Using a ranking based on cell proliferation, inhibitors that 
were shown to potently inhibit the c-Met phenotype, includ-
ing Genentech 5D5 Fab, did not score in the top 10% inhibi-
tors of proliferation (Fig. 4C and Suppl. Fig. S4). Consistent 
Figure 2. c-Met–dependent phenotypic changes. (A) Inhibition of hepatocyte growth factor (HGF)–induced invasion in 3D-cultured 
PC-3 cells by function blocking c-Met Fab antibody 5D5 (Genentech, South San Francisco, CA) and stimulation of invasion by the 
crosslinking and activating bivalent IgG isoform. Principal components analysis (PCA) trained on unstimulated and stimulated control, 
PC0 shown and scaled as Z score to unstimulated control. Results are shown as means of quadruplicate wells and standard deviations. 
(B) 5D5 Fab (triangles) causes a shift in phenotype from stimulated (empty circles) back to unstimulated control (filled circles). Point 
size of markers for Fab treatment increases with concentration (seven concentrations; range, 0.316–316 nM). Individual data points 
are shown as a 3D scatterplot with PC0, PC1, and PC2.
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with the profiling results in Figure 4A, when compounds 
were ranked based on the difference in their phenotypic 
profiles to unstimulated controls (measured along PC0), a 
strong enrichment of c-Met and EGFR inhibitors was 
observed in the top 10% of ranked compounds in the pres-
ence of HGF and EGF, respectively (Suppl. Fig. S4). The 
most potent inhibitors of proliferation were found to per-
form poorly when ranked based on their phenotypic profiles 
(Fig. 4C). An analysis of the images from 3D cultures 
treated with these compounds showed that spheroid forma-
tion was disrupted, consistent with cytotoxicity of these 
compounds.
Discussion
Because tumor cells exist in a 3D ECM-rich environment, 
3D matrix-embedded cell cultures provide a more physio-
logically relevant context in which to perform compound 
Figure 3. Discriminating on-target effects from off-target effects. (A) Hepatocyte growth factor (HGF)–induced (left panel) and 
epidermal growth factor (EGF)–induced (right panel) phenotypes can be inhibited by small molecules targeting c-Met and EGF 
receptor (EGFR), respectively. Responses are shown as PC0, Z score normalized to unstimulated. Values shown as means of 
quadruplicate wells with standard deviation. (B) Principal components analysis (PCA) plot identifies novel phenotype introduced 
by ArQ-197 (triangles) at high doses. Individual data points are shown as a 3D scatterplot with PC0, PC1, and PC2. Empty circles, 
stimulated controls; filled circles, unstimulated controls. (C) Representative images showing HGF- and EGF-induced invasion and 
inhibition by small molecules. Maximum intensity projections of both image channels shown. (D) Western blot of c-Met and EGFR 
phosphorylation in 2D-cultured PC-3 cells exposed to EGF or HGF and inhibitors.
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Figure 4. Identification of selective c-Met/EGFR inhibitors in a Vichem epidermal growth factor (EGF) receptor (EGFR)/c-Met 
inhibiting compound library. (A) Compound screen of 80 Vichem compounds tested at 10, 3.16, and 1µM. Compounds were divided 
over triplicate plates and coexposed with either hepatocyte growth factor (HGF) (20 ng/mL) or EGF (20 ng/mL). Principal components 
analysis (PCA) was trained on unstimulated and stimulated controls separately for plates exposed to HGF or EGF, respectively, to 
obtain a principal component that could separate c-Met and EGFR responses. Data points represent mean determinations from three 
wells. Controls are color-coded as indicated in the legend. For stimulated (top middle) and unstimulated controls (bottom left), a 
2D-density estimation (contour lines) is shown. (B) Representative 2D projected images derived from the F-actin staining after 96 h of 
compound treatment. Except for AG1478, which was 3.16 µM, shown treatment concentrations were 10 µM. Pictures were obtained 
using a BD Pathway 855 microscope (images trimmed to 300 × 300 pixels for presentation purposes). (C) Cell count (viability) is 
a poor criterion for selecting c-Met and EGFR inhibitors. Number of nuclei per well was percent normalized to stimulated control 
(100%) and lowest detected cell count and 0%, top panel. The top ranking 10% of compounds affecting cell count are color-coded in 
red. Middle and lower panels show the same compounds ranked on efficacy on c-Met and EGFR profiles (distance to unstimulated 
control). Mean values shown; each chart contains compounds at three different concentrations.
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screening.2–4 The increased complexity of 3D cultures also 
offers increased potential for phenotypic profiling.27–29 We 
developed a fully scalable 3D tissue culture–based high-
content screening platform that uses phenotypic profiling of 
cultured tumoroids derived from a prostate cancer cell line. 
This screening platform was used to identify several selec-
tive inhibitors for c-Met and EGFR, which represent impor-
tant targets in many cancers and are known to be able to 
stimulate survival and invasive growth of tumours.15–17 We 
show that activation of c-Met with its ligand, HGF, induced 
a dose-dependent reorganization of PC-3 spheroids charac-
terized by invasion of cells into the surrounding matrix. A 
similar change in phenotype was induced by the addition of 
EGF to the PC-3 cells. These phenotypic changes were not 
observed in 2D monolayers. Ultra-high-content multipara-
metric analysis allowed a clear discrimination of the pheno-
types associated with active and inactive c-Met and EGFR, 
which could be quantified using a single PCA measure-
ment. This approach allowed us to discriminate inhibitors 
of c-Met and EGFR and also putative biselective inhibitors 
of these receptor tyrosine kinases. The method also enabled 
nonselective compounds to be discriminated since they 
induced phenotypes that failed to match those induced by 
selective inhibition of c-Met or EGFR. The screening 
results were cross-validated with an in vitro measurement 
of enzyme activity and were found to largely correlate. 
Some compounds that inhibited EGFR or c-Met in the bio-
chemical measurement were not identified by our pheno-
typic screen as inhibitors for these pathways, indicating that 
inhibition of purified enzyme does not always correlate 
with inhibition of the target enzyme in cells. These differ-
ences may be explained by poor compound stability over 
multiple days in aqueous solution (medium) or poor mem-
brane permeability, resulting in lower cytoplasmic concen-
trations. It is also possible that these compounds induce 
mild phenotypic changes that are below the threshold of the 
phenotypic assay. A number of compounds were found to 
induce phenotypic changes in the EGFR and/or c-Met pro-
files, even though these failed to induce inhibition of either 
EGFR or c-Met activity. A possible explanation for this 
finding is that these molecules induced off-target pheno-
typic effects that could not be discriminated from inhibition 
of c-Met and EGFR.
Improvements in 3D cell culture reagents, methods, and 
automated microscopes that can capture 3D image data are 
making screening in 3D more accessible, including more 
complex models such as co-cultures.5,30 Here we describe 
how high-content analysis can maximize the information 
that can be extracted from the more complex phenotypes 
obtained in 3D cell culture. These include disease-relevant 
Table 1. Hit Selection Phenotypic Screen.
Vichem Compound ID 1 µM 3.16 µM 10 µM
VCC030450:22 EGFR EGFR EGFR
VCC048363:02 EGFR EGFR EGFR/c-Met
VCC055393:01 EGFR/c-Met EGFR/c-Met EGFR/c-Met
VCC109756:01 c-Met c-Met c-Met
VCC155409:01 None None EGFR/c-Met
VCC228833:01 None None Top 10% cell count
VCC285946:01 None c-Met c-Met
VCC376189:01 c-Met c-Met EGFR/c-Met
VCC378728:01 None EGFR None
VCC407451:10 None EGFR EGFR
VCC415997:02 c-Met c-Met c-Met
VCC429285:02 None None EGFR/c-Met
VCC444414:01 c-Met c-Met c-Met
VCC450892:17 c-Met c-Met c-Met
VCC497510:01 c-Met c-Met EGFR/c-Met
VCC502987:01 None None EGFR/c-Met
VCC528301:01 None None EGFR/c-Met
VCC656576:02 None None None
VCC716837:01 None None Top 10% cell count
VCC740005:11 None EGFR EGFR
VCC744093:03 None None None
VCC833029:24 None None EGFR
VCC868449:01 None None EGFR/c-Met
VCC960450:01 c-Met c-Met c-Met
EGFR, epidermal growth factor receptor.
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Table 2. Enzyme Activity Measurement (Percent Inhibition).
Inhibition (%)
Vichem 
Compound ID EGFR 10 µM EGFR 1 µM EGFR 0.1 µM c-Met 10 µM c-Met 1 µM c-Met 0.1 µM
VCC030450:22 101 99 97 4 2 0
VCC048363:02 101 100 97 1 –2 –1
VCC055393:01 99 100 100 3 3 –4
VCC109756:01 43 7 2 93 61 7
VCC155409:01 76 34 10 25 2 –2
VCC228833:01 16 1 0 4 0 –2
VCC285946:01 32 0 9 84 49 8
VCC376189:01 12 2 –2 83 56 9
VCC378728:01 85 41 8 72 16 0
VCC407451:10 93 92 73 7 0 –4
VCC415997:02 –11 –11 –7 95 77 14
VCC429285:02 3 2 0 6 –2 2
VCC444414:01 7 –4 –6 90 47 3
VCC450892:17 32 10 5 85 39 4
VCC497510:01 20 10 2 90 54 9
VCC502987:01 19 9 1 4 1 0
VCC528301:01 94 82 29 37 7 1
VCC656576:02
–
2 –7 –13 0 –4 –4
VCC716837:01 48 10 1 41 6 0
VCC740005:11 105 102 93 11 1 3
VCC744093:03 77 25 3 27 –1 –1
VCC833029:24 97 90 37 –3 0 0
VCC868449:01 95 89 37 56 14 3
VCC960450:01 –11 –7 –10 87 50 11
Scale of red to green shading used to visualise % inhibition. Red, no inhibition of target; Yellow, mild target inhibition; Green, potent inhibition of 
target. EGFR, epidermal growth factor receptor.
features, such as tumor cell invasion, but also a multitude of 
other features that can be exploited for profiling purposes. 
Thus, in addition to screening for inhibition of a disease pheno-
type, target-based screening can be performed. Traditionally, 
receptor activation has been measured using biochemical 
methods. While sensitive, these methods do not discriminate 
nonselective inhibition of the target. An advantage of the mul-
tiparametric profiling approach described here is that in 
addition to detecting inhibition of the c-Met and EGFR, off-
target effects can also be detected if the off-targets have an 
impact on tissue phenotype.
Our method was used to determine inhibitory activity of 
both small molecules and antibodies. We applied the method 
to both c-Met and EGFR, but in principle, it can be applied 
to any target if a cell line can be identified in which the 
activity of the target influences cell phenotype. Combining 
the advantages of physiological relevance and phenotypic 
complexity, phenotypic screening and profiling with 3D 
cell cultures has the potential to improve the quality of hits 
from screens and make previously challenging targets more 
accessible, potentially leading to a higher success rate of 
molecules in clinical trials.
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